(1E,4E)-1-(4-Hydroxy-3,5-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1,4-pentadiene-3-one

Curcumin [C0434][C2302] has chemopreventive and chemotherapeutic potentials against various types of cancers, but low bioavailability prevents its use in chemotherapeutic applications. GO-Y078 and GO-Y030 [B4823] are new synthetic analogues of curcumin, developed by Shibata, Iwabuchi et al. to increase its potential and circumvent its low bioavailability.^1,2) In their reports, GO-Y078 and GO-Y030 suppress the growth of myeloma cells, and are 7 to 12 times more effective than curcumin. GO-Y078 and GO-Y030 are also 6- to 15-fold stronger multi-target inhibitors (eg. nuclear factor-κB (NFκB)) than curcumin. Furthermore, GO-Y078 inhibits tumor angiogenesis through actin disorganization.³⁾ In addition, the water solubility of GO-Y078 (1.07 mg/L) is 2 times higher than that of curcumin (0.54 mg/L).⁴⁾ (The product is for research purpose only.)